{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T18:26:59Z","timestamp":1785868019034,"version":"3.56.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteoporosis (OP) is a progressive skeletal disorder often exacerbated by pharmacological agents. Proton pump inhibitors (PPIs), particularly esomeprazole, have been epidemiologically linked to OP, but the underlying mechanisms remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study mined over 55 million adverse event (AE) records from the FDA Adverse Event Reporting System (FAERS) between 2004 and 2024 to identify drug-related OP signals. Four statistical algorithms (ROR, PRR, BCPNN, EBGM) were applied for signal detection. Logistic regression was used to assess independent risk factors. Esomeprazole, the most frequently reported PPI, was further investigated using a network toxicology framework. Drug-target predictions, differential gene expression analysis, protein-protein interaction network construction, molecular docking and molecular dynamics (MD) simulations were conducted to explore potential molecular hypotheses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 52 drugs showed potential OP-related reporting signals. Among PPI-associated OP-related reports, esomeprazole accounted for the largest proportion and was the only PPI with positive signals across all four algorithms. Logistic regression showed that esomeprazole, age, sex, and low body weight were associated with OP-related adverse event reporting. Time-to-onset analysis showed a median latency of 3.5 years. Network toxicology analysis identified 26 overlapping candidate genes between predicted esomeprazole targets and OP-related DEGs. GO and KEGG analyses highlighted bone-related pathways, including MAPK, Notch, and PI3K\/AKT signaling. Protein-protein interaction network analysis identified CXCR4, AKT1, and CASP3 as candidate hub genes. Molecular docking and 100-ns MD simulations supported the binding plausibility and conformational stability of the predicted esomeprazole-target complexes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pharmacovigilance and computational toxicology study suggests a notable association between esomeprazole and PPI-associated OP-related adverse event reporting. The identified targets and pathways, including CXCR4, AKT1, and CASP3, provide exploratory mechanistic clues and hypothesis-generating evidence. These findings may support individualized bone health risk assessment in long-term PPI users and provide a basis for future validation studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0353264","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:25:29Z","timestamp":1785864329000},"page":"e0353264","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["FAERS-based pharmacovigilance and network toxicology analysis of esomeprazole-associated osteoporosis"],"prefix":"10.1371","volume":"21","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0916-1495","authenticated-orcid":true,"given":"Jue","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"pone.0353264.ref001","article-title":"Epidemiology, etiology, and diagnosis of osteoporosis","volume":"194","author":"NE Lane","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"pone.0353264.ref002","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mcna.2022.10.013","article-title":"Osteoporosis","volume":"107","author":"V Gopinath","year":"2023","journal-title":"Med Clin N Am"},{"issue":"9321","key":"pone.0353264.ref003","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"JA Kanis","year":"2002","journal-title":"Lancet"},{"key":"pone.0353264.ref004","doi-asserted-by":"crossref","first-page":"117103","DOI":"10.1016\/j.envres.2023.117103","article-title":"A comprehensive review on environmental pollutants and osteoporosis: insights into molecular pathways","volume":"237","author":"P Snega Priya","year":"2023","journal-title":"Environ Res"},{"issue":"1","key":"pone.0353264.ref005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"E Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"issue":"10","key":"pone.0353264.ref006","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14740338.2018.1524868","article-title":"Drug-induced bone loss: a major safety concern in Europe","volume":"17","author":"K-D Nguyen","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"pone.0353264.ref007","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae598","article-title":"Sex-specific association of chronic proton pump inhibitor use with reduced bone density and quality","volume":"110","author":"F Bioletto","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"pone.0353264.ref008","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"LE Targownik","year":"2008","journal-title":"CMAJ"},{"issue":"24","key":"pone.0353264.ref009","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Y-X Yang","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"pone.0353264.ref010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1753-4887.2008.00015.x","article-title":"Proton pump-inhibiting drugs, calcium homeostasis, and bone health","volume":"66","author":"MJ Wright","year":"2008","journal-title":"Nutr Rev"},{"issue":"6","key":"pone.0353264.ref011","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae598","article-title":"Sex-specific association of chronic proton pump inhibitor use with reduced bone density and quality","volume":"110","author":"F Bioletto","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"pone.0353264.ref012","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00774-015-0699-6","article-title":"Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors","volume":"34","author":"E Bahtiri","year":"2016","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"pone.0353264.ref013","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.11.023","article-title":"Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women","volume":"156","author":"KE Hansen","year":"2019","journal-title":"Gastroenterology"},{"issue":"12","key":"pone.0353264.ref014","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.jaip.2025.07.039","article-title":"Anaphylaxis to Penicillin: harvesting insights from the food and drug administration\u2019s adverse event reporting system","volume":"13","author":"AP Belmont","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"pone.0353264.ref015","article-title":"Transparency in the reporting of artificial intelligence \u2013 the TITAN guideline","volume":"2","author":"AA Riaz","year":"2025","journal-title":"Premier J Sci"},{"key":"pone.0353264.ref016","doi-asserted-by":"crossref","DOI":"10.5772\/50095","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS).","volume-title":"Data mining applications in engineering and medicine","author":"E Poluzzi","year":"2012"},{"issue":"1","key":"pone.0353264.ref017","article-title":"Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen","volume":"259","author":"L Lu","year":"2023","journal-title":"J Endocrinol"},{"key":"pone.0353264.ref018","article-title":"Estrogen and bone metabolism","author":"HK V\u00e4\u00e4n\u00e4nen","year":"1996","journal-title":"Maturitas"},{"key":"pone.0353264.ref019","doi-asserted-by":"crossref","DOI":"10.1093\/ajcn\/63.3.433","article-title":"Putting body weight and osteoporosis into perspective","volume":"63","author":"GM Wardlaw","year":"1996","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"pone.0353264.ref020","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00198-003-1487-z","article-title":"Superiority of age and weight as variables in predicting osteoporosis in postmenopausal white women","volume":"14","author":"M Wildner","year":"2003","journal-title":"Osteoporos Int"},{"issue":"10","key":"pone.0353264.ref021","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"MS LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"key":"pone.0353264.ref022","doi-asserted-by":"crossref","first-page":"109302","DOI":"10.1016\/j.intimp.2022.109302","article-title":"Single-cell RNA sequencing analysis dissected the osteo-immunology microenvironment and revealed key regulators in osteoporosis","volume":"113","author":"Y Wang","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"pone.0353264.ref023","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.3390\/ijms24065814","article-title":"Hormone-related and drug-induced osteoporosis: a cellular and molecular overview","volume":"24","author":"L-T Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0353264.ref024","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.maturitas.2009.07.006","article-title":"Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures","volume":"64","author":"MR Fournier","year":"2009","journal-title":"Maturitas"},{"key":"pone.0353264.ref025","doi-asserted-by":"crossref","first-page":"1592048","DOI":"10.3389\/fphar.2025.1592048","article-title":"Exploring the mechanisms and targets of proton pump inhibitors-induced osteoporosis through network toxicology, molecular docking, and molecular dynamics simulations","volume":"16","author":"Y Mu","year":"2025","journal-title":"Front Pharmacol"},{"issue":"9","key":"pone.0353264.ref026","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","article-title":"Proton pump inhibitor use: systematic review of global trends and practices","volume":"79","author":"LGT Shanika","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pone.0353264.ref027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.11005\/jbm.25.841","article-title":"Comparison of differences in cell migration during the osteogenic and adipogenic differentiation of the bone marrow-derived stem cells","volume":"32","author":"A Sardar","year":"2025","journal-title":"J Bone Metab"},{"key":"pone.0353264.ref028","first-page":"9823784","article-title":"Engineering stem cell recruitment and osteoinduction via bioadhesive molecular mimics to improve osteoporotic bone-implant integration","volume":"2022","author":"J Bai","year":"2022","journal-title":"Research (Wash)"},{"issue":"4","key":"pone.0353264.ref029","article-title":"Synthetic biology-based bacterial extracellular vesicles displaying BMP-2 and CXCR4 to ameliorate osteoporosis","volume":"13","author":"H Liu","year":"2024","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"pone.0353264.ref030","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41467-023-37791-4","article-title":"WHIM syndrome-linked CXCR4 mutations drive osteoporosis","volume":"14","author":"A Anginot","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"pone.0353264.ref031","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"JA Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"pone.0353264.ref032","doi-asserted-by":"crossref","first-page":"116752","DOI":"10.1016\/j.bcp.2025.116752","article-title":"5,7-Dihydroxy-4-Methylcoumarin enhances osteogenesis and ameliorates osteoporosis via the AKT1 pathway","volume":"233","author":"H Diao","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"pone.0353264.ref033","doi-asserted-by":"crossref","first-page":"152015","DOI":"10.1016\/j.bbrc.2025.152015","article-title":"SRSF1 and SRSF2 synergistically regulate Bim expression to mediate glucocorticoid-induced apoptosis in osteoblasts","volume":"770","author":"H Luo","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"pone.0353264.ref034","first-page":"7249","article-title":"MiR-378 overexpression attenuates high glucose-suppressed osteogenic differentiation through targeting CASP3 and activating PI3K\/Akt signaling pathway","volume":"7","author":"L You","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"pone.0353264.ref035","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semcdb.2008.07.016","article-title":"Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption","volume":"19","author":"NA Sims","year":"2008","journal-title":"Semin Cell Dev Biol"},{"issue":"8","key":"pone.0353264.ref036","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"P Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"pone.0353264.ref037","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz338","article-title":"Impact of Tenofovir-based pre-exposure prophylaxis on biomarkers of bone formation, bone resorption, and bone mineral metabolism in HIV-negative adults","volume":"6","author":"TL Nickolas","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"pone.0353264.ref038","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/ijms26031202","article-title":"Network pharmacology analysis and biological validation systemically identified the active ingredients and molecular targets of Kudzu root on osteoporosis","volume":"26","author":"Z-W Liu","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:25:36Z","timestamp":1785864336000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353264"}},"subtitle":[],"editor":[{"given":"Satish","family":"Rojekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0353264","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}